Inventor · disambiguated record
Michael L. Mccaleb
Also filed as: MCCALEB MICHAEL L
18 granted patents·16 pending applications·157 citations·filing 1989–2024
94Inventor score
Files withIONIS PHARMACEUTICALS INC22BAYER AG5ISIS PHARMACEUTICALS INC3AMERICAN HOME PROD1BAYER CORP1
Top patents by PatentIndex Score
34 records- 0197US8642752B2Modulation of Hepatitis B virus (HBV) expressionSWAYZE ERIC E·Filed 2012·Granted Feb 4, 2014·41 cites·37 claims
- 0294US9340784B2Methods and compositions for modulating alpha-1-antitrypsin expressionIONIS PHARMACEUTICALS INC·Filed 2013·Granted May 17, 2016·11 cites·14 claims
- 0392US11744846B2Allele specific modulators of P23H rhodopsinIONIS PHARMACEUTICALS INC·Filed 2021·Granted Sep 5, 2023·2 cites·14 claims
- 0492US10280423B2Compositions and methods for modulating complement factor B expressionIONIS PHARMACEUTICALS INC·Filed 2015·Granted May 7, 2019·10 cites·36 claims
- 0591US10426789B2Allele specific modulators of P23H rhodopsinIONIS PHARMACEUTICALS INC·Filed 2016·Granted Oct 1, 2019·6 cites·23 claims
- 0691US9034841B2Modulation of hepatitis B virus (HBV) expressionISIS PHARMACEUTICALS INC·Filed 2013·Granted May 19, 2015·9 cites·20 claims
- 0790US9796976B2Methods and compositions for modulating alpha-1 antitrypsin expressionIONIS PHARMACEUTICALS INC·Filed 2016·Granted Oct 24, 2017·3 cites·18 claims
- 0887US2024247268A1Modulators of Complement Factor BIONIS PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 0986US11013758B2Allele specific modulators of P23H rhodopsinIONIS PHARMACEUTICALS INC·Filed 2019·Granted May 25, 2021·2 cites·10 claims
- 1085US2023357776A1Compositions and methods for modulating complement factor b expressionIONIS PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 1181US2023212564A1Methods and compositions for modulating alpha-1-antitrypsin expressionIONIS PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 1279US2022064650A1Modulation of hepatitis b virus (hbv) expressionIONIS PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 1378US11926830B2Modulators of Complement Factor BIONIS PHARMACEUTICALS INC·Filed 2021·Granted Mar 12, 2024·0 cites·25 claims
- 1478US11732265B2Compositions and methods for modulating complement factor B expressionIONIS PHARMACEUTICALS INC·Filed 2021·Granted Aug 22, 2023·0 cites·28 claims
- 1577US5919901ANeuropeptide Y receptor Y5 and nucleic acid sequencesBAYER AG·Filed 1996·Granted Jul 6, 1999·34 cites·6 claims
- 1675US9677076B2Modulation of hepatitis B virus (HBV) expressionIONIS PHARMACEUTICALS INC·Filed 2015·Granted Jun 13, 2017·1 cites·21 claims
- 1774US2020157535A1Methods and compositions for modulating alpha-1-antitrypsin expressionIONIS PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 1874US2022073913A1Methods and compositions for modulating alpha-1-antitrypsin expressionIONIS PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 1973US2020190520A1Modulation of hepatitis b virus (hbv) expressionIONIS PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 2072US5965392ANeuropeptide Y receptor Y5 and nucleic acid sequencesBAYER AG·Filed 1997·Granted Oct 12, 1999·23 cites·38 claims
- 2172US2020149047A1Modulators of complement factor bIONIS PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 2269US2018230465A1Methods and compositions for modulating alpha-1-antitrypsin expressionIONIS PHARMACEUTICALS INC·Filed 2017·Application pending·0 cites
- 2365US2020048638A1Compositions and methods for modulating complement factor b expressionIONIS PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 2463US2017369883A1Modulation of hepatitis b virus (hbv) expressionIONIS PHARMACEUTICALS INC·Filed 2017·Application pending·0 cites
- 2563US2016222389A1Modulators of complement factor bIONIS PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 2661US2019048351A1Modulators of complement factor bIONIS PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 2756US2006189530A1Neuropeptide Y receptor Y5 and nucleic acid sequencesBAYER CORP·Filed 2006·Application pending·0 cites
- 2854US8933213B2Antisense modulation of fibroblast growth factor receptor 4 expressionISIS PHARMACEUTICALS INC·Filed 2012·Granted Jan 13, 2015·0 cites·9 claims
- 2954US2015184164A1Antisense modulation of fibroblast growth factor receptor 4 expressionISIS PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 3052US4910019AOxathiadiazole growth promotersAMERICAN HOME PROD·Filed 1989·Granted Mar 20, 1990·3 cites·10 claims
- 3150US2003022283A1Neuropeptide Y receptor Y5 and nucleic acid sequencesFiled 2001·Application pending·0 cites
- 3242US6410686B1Galanin receptor 2 proteinBAYER AG·Filed 1996·Granted Jun 25, 2002·9 cites·2 claims
- 3339US6207799B1Neuropeptide Y receptor Y5 and nucleic acid sequencesBAYER AG·Filed 1999·Granted Mar 27, 2001·2 cites·2 claims
- 3435US6368824B1Neuropeptide Y receptor Y5 and nucleic acid sequencesBAYER AG·Filed 1999·Granted Apr 9, 2002·1 cites·15 claims
Join the waitlist — get patent alerts
Get an alert when Michael L. Mccaleb files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →